Results 141 to 150 of about 232,899 (308)

WTAP‐Mediated m6A Modification Targets the LRP1‐Lipid Metabolism Axis to Regulate Joint Cartilage Regeneration

open access: yesAdvanced Science, EarlyView.
WTAP drives cartilage regeneration by activating an LRP1‐dependent lipid metabolic program in macrophages, enhancing IL‐10 and TGF‐β secretion to promote chondrogenic differentiation. Leveraging this mechanism, virtual screening identifies LRP1‐targeting compounds that effectively stimulate cartilage repair, highlighting a druggable epigenetic ...
Chenyan Huang   +6 more
wiley   +1 more source

Structure-based inhibitor design of mutant RAS proteins-a paradigm shift. [PDF]

open access: yesCancer Metastasis Rev, 2020
Nyíri K, Koppány G, Vértessy BG.
europepmc   +1 more source

A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. [PDF]

open access: yesJ Pancreat Cancer, 2021
Muscarella P   +15 more
europepmc   +1 more source

Localization of two transmembrane H-Ras proteins

open access: yes, 2004
H-Ras, a small G protein, can activate several downstream effectors and cause diverse effects in the cell. These effects include cell cycle and gene transcription regulation.
Price, Jessica
core   +1 more source

Master Regulator SMC1A, Stabilized by N6‐Methyladenosine Reader IGF2BP1, Promotes HCC Progression Through Facilitating Enhancer–Promoter Interaction of Nestin

open access: yesAdvanced Science, EarlyView.
IGF2BP1‐mediated m6A stabilization sustains SMC1A expression, enabling cohesin‐associated chromatin regulation of Nestin in hepatocellular carcinoma. This work reveals an epitranscriptomic‐chromatin‐cytoskeletal regulatory axis linked to malignant phenotypes and identifies SMC1A as a biologically relevant vulnerability in HCC.
Zhenxiang Peng   +7 more
wiley   +1 more source

Crystal structure of NRAS Q61K with a ligand-induced pocket near switch II

open access: yesEuropean Journal of Cell Biology
The RAS isoforms (KRAS, HRAS and NRAS) have distinct cancer type-specific profiles. NRAS mutations are the second most prevalent RAS mutations in skin and hematological malignancies.
Teklab Gebregiworgis   +5 more
doaj   +1 more source

Synthesis of palmitoylated Ras-peptides and -proteins

open access: yes, 2006
In this review, an overview is given and details are provided for the synthesis of lipidated Ras (rat-adeno-sarcoma)-peptides and -proteins. The progress made in the synthesis of the lipidated peptides from the Ras superfamily is discussed with special ...
Kuhlmann, J.   +6 more
core   +1 more source

Targeting Golgi–STING Signaling to Reprogram Innate and Adaptive Immunity for the Treatment of Implant‐Associated Infections

open access: yesAdvanced Science, EarlyView.
This study presents an ultrasound‐responsive nanoplatform, CS‐BT@MZ@NEs, with a BaTiO3/Mn‐Zif‐8 core and a chondroitin sulfate coating for Golgi targeting. By leveraging neutrophil hitchhiking, it enables targeted delivery to infection sites. Under ultrasound stimulation, CS‐BT@MZ@NEs generates ROS and modulates Golgi pH to activate cGAS–STING ...
Shicheng Huo   +7 more
wiley   +1 more source

K128 ubiquitination constrains RAS activity by expanding its binding interface with GAP proteins

open access: yesThe EMBO Journal
The RAS pathway is among the most frequently activated signaling nodes in cancer. However, the mechanisms that alter RAS activity in human pathologies are not entirely understood.
Wout Magits   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy